Skip to Content

Ionis Pharmaceuticals Inc IONS Stock Quote

| Rating as of

NASDAQ:IONS

Morningstar‘s Stock Analysis IONS

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Maintaining Our $62 FVE for Ionis Following In Line Q3; Late-Stage Pipeline Advancing

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

Ionis reported solid third-quarter results that put it on track to meet our full-year estimates, and we’re maintaining our $62 fair value estimate for the firm. Revenue grew 20% despite declines in royalties for spinal muscular atrophy drug Spinraza, as collaboration revenue from partners Roche, AstraZeneca, and Biogen drove growth. Management maintained its full-year guidance, although we think operating expenses are tracking well below management’s targeted range, despite supporting additional phase 3 programs. Ionis is also sitting on roughly $2 billion in cash, which should support further in-house phase 3 programs and any bolt-on acquisitions necessary to support further advancement of its pipeline of antisense drugs and support its narrow moat.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics IONS

Company Profile IONS

Business Description

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Contact
2855 Gazelle Court
Carlsbad, CA, 92010
T +1 760 931-9200
Industry Biotechnology
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 660

Related News IONS